Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Trial Profile

Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Pralatrexate (Primary)
  • Indications T cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Mundipharma International
  • Most Recent Events

    • 03 Aug 2017 Planned End Date changed from 1 Dec 2015 to NULL.
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 01 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top